Using advanced HDX-MS and native MS techniques can improve the identification of potentially successful biologic drugs and de-risk CMC and clinical designs.
Jennifer S. Chadwick
Advertisement
Jennifer S. Chadwick, PhD, is director of biologic development at BioAnalytix.
Articles by Jennifer S. Chadwick
Advertisement
Latest Updated Articles
De-risking Biologics Development Through Advanced Mass Spectrometry ApproachesPublished: August 1st 2019 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
2
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
3
Everything to Know About Cell and Gene Therapy in 2025
4
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
5
